[Prospects of the use of neoplasm antigens as markers of gynecologic diseases].

article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-08

CA-125 levels were elevated in patients with endometriosis and ovarian tumors, with levels decreasing post-surgery, suggesting its utility in monitoring gynecologic disease treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CA-125 antigen was assayed in 108 patients with the most prevalent gynecologic diseases by enzyme immunoassay. Its blood levels were found to be under 35 U/ml in the patients with inflammatory diseases. In endometriosis and benign ovarian tumors CA-125 concentrations in the blood were elevated. Malignant tumors of the ovaries were detected in 80 percent of the examinees. CA-125 levels reduced after surgical treatment in 72 percent of patients. These data permit a conclusion that CA-125 diagnostic agent may be used to monitor the course of the postoperative period and assess the late results of treatment.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antigens, Tumor-Associated, Carbohydrate Genital Diseases, Female Adolescent Adult Antigens, Tumor-Associated, Carbohydrate Diagnosis, Differential Endometriosis Endometriosis Endometriosis Female Genital Diseases, Female Genital Diseases, Female Humans Immunoenzyme Techniques Middle Aged Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Prognosis Uterine Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:12:15.619952+00:00
License: CC0 · commercial use OK